Published in J Virol on June 01, 1989
Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding. J Exp Med (1991) 9.28
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Crystal structures of the trimeric human immunodeficiency virus type 1 matrix protein: implications for membrane association and assembly. Proc Natl Acad Sci U S A (1996) 4.83
Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci U S A (1990) 4.46
Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding. J Virol (1993) 4.22
Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J Virol (1993) 4.19
Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization. J Virol (1991) 3.71
Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. J Virol (1991) 3.62
Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity. J Virol (1992) 3.54
Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol (1994) 3.32
A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity. Proc Natl Acad Sci U S A (1992) 3.01
Attenuation of human immunodeficiency virus type 1 cytopathic effect by a mutation affecting the transmembrane envelope glycoprotein. J Virol (1991) 2.77
Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J Virol (1990) 2.58
Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol (2006) 2.57
Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol (2011) 2.34
Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein. J Virol (1993) 2.21
The ectodomain of HIV-1 env subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the absence of gp120 and the N-terminal fusion peptide. EMBO J (1996) 2.21
Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol (2001) 2.16
A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J Virol (1998) 2.12
Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies. Proc Natl Acad Sci U S A (1994) 2.09
Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J Virol (1997) 2.08
Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro. Proc Natl Acad Sci U S A (1990) 2.08
HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol (2011) 2.01
Truncation of the cytoplasmic domain of the simian immunodeficiency virus envelope glycoprotein alters the conformation of the external domain. J Virol (1994) 2.00
Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol (1991) 2.00
Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41. J Virol (2000) 1.78
Analysis of the interaction of the human immunodeficiency virus type 1 gp120 envelope glycoprotein with the gp41 transmembrane glycoprotein. J Virol (1997) 1.77
The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope. J Virol (1990) 1.76
A specific inhibitor of cysteine proteases impairs a Vif-dependent modification of human immunodeficiency virus type 1 Env protein. J Virol (1991) 1.72
Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. J Virol (1997) 1.72
A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody. J Virol (1994) 1.72
Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med (1991) 1.71
Functional role of the zipper motif region of human immunodeficiency virus type 1 transmembrane protein gp41. J Virol (1994) 1.61
An amphipathic peptide from the C-terminal region of the human immunodeficiency virus envelope glycoprotein causes pore formation in membranes. J Virol (1994) 1.59
Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain. J Virol (1998) 1.58
Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker. J Virol (2006) 1.58
Humoral response to oligomeric human immunodeficiency virus type 1 envelope protein. J Virol (1996) 1.57
Human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus env proteins possess a functionally conserved assembly domain. J Virol (1990) 1.56
Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. J Virol (2002) 1.54
Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain. J Virol (1995) 1.52
Stimulation of glycoprotein gp120 dissociation from the envelope glycoprotein complex of human immunodeficiency virus type 1 by soluble CD4 and CD4 peptide derivatives: implications for the role of the complementarity-determining region 3-like region in membrane fusion. Proc Natl Acad Sci U S A (1991) 1.48
The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts. J Virol (2000) 1.47
gp160, the envelope glycoprotein of human immunodeficiency virus type 1, is a dimer of 125-kilodalton subunits stabilized through interactions between their gp41 domains. J Virol (1991) 1.45
Oligomerization of the hydrophobic heptad repeat of gp41. J Virol (1995) 1.38
Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope. J Virol (1999) 1.38
Role of N-linked glycans of envelope glycoproteins in infectivity of human immunodeficiency virus type 1. J Virol (1990) 1.35
The human immunodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in promotion of HIV-1 infection. Microbiol Rev (1995) 1.34
Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies. Nat Struct Mol Biol (2010) 1.33
Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site. J Biol Chem (2011) 1.32
Regulation of virus release by the macrophage-tropic human immunodeficiency virus type 1 AD8 isolate is redundant and can be controlled by either Vpu or Env. J Virol (1999) 1.31
Human immunodeficiency virus type 1 envelope glycoprotein oligomerization requires the gp41 amphipathic alpha-helical/leucine zipper-like sequence. J Virol (1997) 1.31
Human foamy virus polypeptides: identification of env and bel gene products. J Virol (1993) 1.30
Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140. J Virol (1998) 1.27
Recombinant CD4-selected human immunodeficiency virus type 1 variants with reduced gp120 affinity for CD4 and increased cell fusion capacity. J Virol (1991) 1.26
Transmembrane envelope glycoproteins of human immunodeficiency virus type 2 and simian immunodeficiency virus SIV-mac exist as homodimers. J Virol (1990) 1.26
Characterization of monoclonal antibodies against the human immunodeficiency virus matrix protein, p17gag: identification of epitopes exposed at the surfaces of infected cells. J Virol (1991) 1.21
Multimeric CD4 binding exhibited by human and simian immunodeficiency virus envelope protein dimers. J Virol (1992) 1.21
Requirement of N-terminal amino acid residues of gp41 for human immunodeficiency virus type 1-mediated cell fusion. J Virol (1995) 1.20
Association of human immunodeficiency virus type 1 envelope glycoprotein with particles depends on interactions between the third variable and conserved regions of gp120. J Virol (1993) 1.20
Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure. J Virol (1995) 1.19
Conserved cysteine residues in the human immunodeficiency virus type 1 transmembrane envelope protein are essential for precursor envelope cleavage. J Virol (1992) 1.15
Quaternary structures of HIV Env immunogen exhibit conformational vicissitudes and interface diminution elicited by ligand binding. Proc Natl Acad Sci U S A (2011) 1.10
The tale of the long tail: the cytoplasmic domain of HIV-1 gp41. J Virol (2012) 1.09
Biophysical characterization of recombinant proteins expressing the leucine zipper-like domain of the human immunodeficiency virus type 1 transmembrane protein gp41. J Virol (1996) 1.07
A rat CD4 mutant containing the gp120-binding site mediates human immunodeficiency virus type 1 infection. J Exp Med (1993) 1.07
Mechanisms of human immunodeficiency virus Type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody. J Virol (1996) 1.07
Live simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry. J Immunol (2014) 1.04
Biochemical characterization of the structural and nonstructural polypeptides of a porcine group C rotavirus. J Virol (1990) 1.04
Transmembrane protein oligomers of caprine arthritis-encephalitis lentivirus are immunodominant in goats with progressive arthritis. J Virol (1992) 1.03
The YXXL sequences of a transmembrane protein of bovine leukemia virus are required for viral entry and incorporation of viral envelope protein into virions. J Virol (1999) 1.03
Oligomer-specific conformations of the human immunodeficiency virus (HIV-1) gp41 envelope glycoprotein ectodomain recognized by human monoclonal antibodies. AIDS Res Hum Retroviruses (2009) 1.00
Mutations in the leucine zipper-like heptad repeat sequence of human immunodeficiency virus type 1 gp41 dominantly interfere with wild-type virus infectivity. J Virol (1998) 1.00
Membrane permeabilization by different regions of the human immunodeficiency virus type 1 transmembrane glycoprotein gp41. J Virol (1995) 0.98
Cell surface expression of the HIV-1 envelope glycoproteins is directed from intracellular CTLA-4-containing regulated secretory granules. Proc Natl Acad Sci U S A (2002) 0.97
The SU and TM envelope protein subunits of bovine leukemia virus are linked by disulfide bonds, both in cells and in virions. J Virol (2000) 0.97
Structure and genetic variability of envelope glycoproteins of two antigenic variants of caprine arthritis-encephalitis lentivirus. J Virol (1991) 0.96
Demonstration of two distinct cytopathic effects with syncytium formation-defective human immunodeficiency virus type 1 mutants. J Virol (1991) 0.96
Human immunodeficiency virus type 1 and 2 envelope glycoproteins oligomerize through conserved sequences. J Virol (1997) 0.95
Antibody-mediated enhancement of human immunodeficiency virus type 1 infectivity is determined by the structure of gp120 and depends on modulation of the gp120-CCR5 interaction. J Virol (2002) 0.94
C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic. J Gen Virol (2012) 0.93
gp120-independent fusion mediated by the human immunodeficiency virus type 1 gp41 envelope glycoprotein: a reassessment. J Virol (1994) 0.92
Induction of antibodies to the envelope protein of the human immunodeficiency virus by immunization with monoclonal anti-idiotypes. Proc Natl Acad Sci U S A (1991) 0.91
Mutational analysis of the oligomer assembly domain in the transmembrane subunit of the Rous sarcoma virus glycoprotein. J Virol (1997) 0.91
Expression of the TM protein of Rous sarcoma virus in the absence of SU shows that this domain is capable of oligomerization and intracellular transport. J Virol (1994) 0.91
Distinct mechanisms of neutralization by monoclonal antibodies specific for sites in the N-terminal or C-terminal domain of murine leukemia virus SU. J Virol (2003) 0.89
A molecular model for membrane fusion based on solution studies of an amphiphilic peptide from HIV gp41. Protein Sci (1992) 0.88
Human monoclonal antibody 2909 binds to pseudovirions expressing trimers but not monomeric HIV-1 envelope proteins. Hum Antibodies (2009) 0.88
Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potency. Protein Sci (2008) 0.87
Functional role of the glycan cluster of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) ectodomain. J Virol (1993) 0.86
Inhibition of alpha-glucosidase I of the glycoprotein-processing enzymes by 6-O-butanoyl castanospermine (MDL 28,574) and its consequences in human immunodeficiency virus-infected T cells. Antimicrob Agents Chemother (1994) 0.86
Involvement of the C-terminal disulfide-bonded loop of murine leukemia virus SU protein in a postbinding step critical for viral entry. J Virol (2005) 0.81
Anti-human immunodeficiency virus type 1 antibodies of noninfected subjects are not related to autoantibodies occurring in systemic diseases. Clin Diagn Lab Immunol (1995) 0.80
Trimeric HIV Env provides epitope occlusion mediated by hypervariable loops. Sci Rep (2014) 0.80
Reproducing SIVΔnef vaccine correlates of protection: trimeric gp41 antibody concentrated at mucosal front lines. AIDS (2016) 0.79
Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41. Curr HIV Res (2016) 0.77
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels. Eur J Biochem (1974) 113.22
Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature (1981) 24.17
Molecular weight determination of protein-dodecyl sulfate complexes by gel electrophoresis in a discontinuous buffer system. J Biol Chem (1971) 16.34
Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science (1987) 13.52
Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). Science (1985) 10.97
Expression of wild-type and mutant forms of influenza hemagglutinin: the role of folding in intracellular transport. Cell (1986) 9.16
Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science (1985) 8.53
Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins. Virology (1987) 7.92
Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. Science (1985) 6.48
Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160. Proc Natl Acad Sci U S A (1988) 6.33
Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution. Nature (1983) 5.56
Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science (1985) 5.42
Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science (1986) 5.25
Oligomerization is essential for transport of vesicular stomatitis viral glycoprotein to the cell surface. Cell (1986) 5.19
Assembly of influenza hemagglutinin trimers and its role in intracellular transport. J Cell Biol (1986) 4.93
Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc Natl Acad Sci U S A (1986) 4.68
Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J (1986) 4.32
Isolation of coronavirus envelope glycoproteins and interaction with the viral nucleocapsid. J Virol (1980) 3.82
Generation of human monoclonal antibodies to human immunodeficiency virus. Proc Natl Acad Sci U S A (1989) 3.07
Oligomeric structure of a prototype retrovirus glycoprotein. Proc Natl Acad Sci U S A (1988) 3.06
Shedding and interspecies type sero-reactivity of the envelope glycopolypeptide gp120 of the human immunodeficiency virus. J Gen Virol (1986) 2.65
Quaternary structure of influenza virus hemagglutinin after acid treatment. J Virol (1986) 2.54
Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120. Proc Natl Acad Sci U S A (1988) 2.34
Identification and antigenicity of the major envelope glycoprotein of lymphadenopathy-associated virus. Virology (1985) 2.23
Purified envelope glycoproteins from human immunodeficiency virus type 1 variants induce individual, type-specific neutralizing antibodies. J Virol (1988) 1.95
Structural studies of retroviruses: characterization of oligomeric complexes of murine and feline leukemia virus envelope and core components formed upon cross-linking. J Virol (1979) 1.90
O-linked glycosylation of retroviral envelope gene products. J Virol (1988) 1.75
Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine. Proc Natl Acad Sci U S A (1987) 1.46
Murine mammary tumor virus structural protein interactions: formation of oligomeric complexes with cleavable cross-linking agents. J Virol (1980) 1.24
Nearest-neighbor interactions of the major RNA tumor virus glycoprotein on murine cell surfaces. Proc Natl Acad Sci U S A (1978) 1.16
A sensitive radioimmunoprecipitation assay for human immunodeficiency virus (HIV). J Immunol Methods (1988) 1.15
Disseminated Kaposi's sarcoma in homosexual men. Ann Intern Med (1982) 4.98
Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science (1983) 4.72
Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol (1992) 4.72
Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol (1991) 3.93
Defining criteria for autoimmune diseases (Witebsky's postulates revisited) Immunol Today (1993) 3.81
Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J Immunol (1993) 3.39
Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D. J Virol (1994) 3.33
Generation of human monoclonal antibodies to human immunodeficiency virus. Proc Natl Acad Sci U S A (1989) 3.07
Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology (1995) 3.06
Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of human immunodeficiency virus type 1. J Virol (1994) 2.96
Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci U S A (1991) 2.85
Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol (1998) 2.83
A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity. Res Virol (1992) 2.74
Immunologic abnormalities in homosexual men. Relationship to Kaposi's sarcoma. Am J Med (1982) 2.71
Cellular basis of regulation of expression of idiotype. I. T-suppressor cells specific for MOPC 460 idiotype regulate the expression of cells secreting anti-TNP antibodies bearing 460 idiotype. J Exp Med (1979) 2.53
Inhibition of virus attachment to CD4+ target cells is a major mechanism of T cell line-adapted HIV-1 neutralization. J Exp Med (1997) 2.31
Mitogenic effect of bacterial peptidoglycans possessing adjuvant activity. J Immunol (1975) 2.15
Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med (1995) 2.12
High frequency of autoreactive myelin proteolipid protein-specific T cells in the periphery of naive mice: mechanisms of selection of the self-reactive repertoire. J Exp Med (2000) 2.10
Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro. Proc Natl Acad Sci U S A (1990) 2.08
Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol (1991) 2.00
Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins. J Virol (1999) 1.97
Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M. J Virol (2000) 1.96
Presentation of a viral T cell epitope expressed in the CDR3 region of a self immunoglobulin molecule. Science (1993) 1.96
Production of human monoclonal antibodies specific for conformational and linear non-V3 epitopes of gp120. AIDS Res Hum Retroviruses (1992) 1.94
Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity. J Immunol (1997) 1.89
Influenza A virus transfectants with chimeric hemagglutinins containing epitopes from different subtypes. J Virol (1992) 1.88
Structural domains of endogenous murine leukemia virus gp70s containing specific antigenic determinants defined by monoclonal antibodies. Virology (1982) 1.88
Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. AIDS Res Hum Retroviruses (1992) 1.85
Serotyping of primary human immunodeficiency virus type 1 isolates from diverse geographic locations by flow cytometry. J Virol (1995) 1.80
Potent neutralization of primary HIV-1 isolates by antibodies directed against epitopes present in the V1/V2 domain of HIV-1 gp120. Vaccine (1998) 1.79
Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41. J Virol (2000) 1.78
Cellular basis of regulation of expression of idiotype. II. Immunity to anti-MOPC-460 idiotype antibodies increases the level of anti-trinitrophenyl antibodies bearing 460 idiotypes. J Exp Med (1979) 1.76
Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. J Virol (1998) 1.75
O-linked glycosylation of retroviral envelope gene products. J Virol (1988) 1.75
A novel, glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent, neutralizing chimpanzee monoclonal antibody. J Virol (1994) 1.72
Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1. J Virol (1993) 1.70
Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J Immunol (1990) 1.68
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis (1998) 1.64
Blastic transformtion of mouse spleen lymphocytes by a water-soluble mitogen extracted from Nocardia. Proc Natl Acad Sci U S A (1974) 1.62
Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med (1997) 1.62
Identification of HIV vaccine candidate peptides by screening random phage epitope libraries. Virology (1993) 1.60
Host cell-dependent alterations in envelope components of human immunodeficiency virus type 1 virions. J Virol (1997) 1.59
Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies. J Virol (1994) 1.57
Immune response to levan. I. Kinetics and ontogeny of anti-levan and anti-inulin antibody response and of expression of cross-reactive idiotype. J Immunol (1978) 1.57
Proteases as mitogens. The Effect of trypsin and pronase on mouse and human lymphocytes. Exp Cell Res (1974) 1.56
Amino acid residues of the human immunodeficiency virus type I gp120 critical for the binding of rat and human neutralizing antibodies that block the gp120-sCD4 interaction. Virology (1992) 1.56
Isolation of mitogenic and adjuvant active fractions from various species of Nocardiae. Infect Immun (1975) 1.54
Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains. AIDS Res Hum Retroviruses (1992) 1.53
V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (2001) 1.52
Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain. J Virol (1995) 1.52
Kaposi's sarcoma in homosexual men. A seroepidemiologic case-control study. Ann Intern Med (1984) 1.50
Identification of a new V kappa gene family that is highly expressed in hybridomas from an autoimmune mouse strain. J Immunol (1990) 1.46
Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies. Int Immunol (1997) 1.46
Conditions that induce tolerance in mature CD4+ T cells. J Exp Med (1997) 1.45
Topography of murine leukemia virus envelope proteins: characterization of transmembrane components. J Virol (1983) 1.45
Human humoral responses to antigens of Mycobacterium tuberculosis: immunodominance of high-molecular-mass antigens. Clin Diagn Lab Immunol (1997) 1.43
Mitogenic effect of a water-soluble extract of Nocardia opaca: a comparative study with some bacterial adjuvants on spleen and peripheral lymphocytes of four mammalian species. J Immunol (1974) 1.40
Serodiagnostic potential of culture filtrate antigens of Mycobacterium tuberculosis. Clin Diagn Lab Immunol (2000) 1.39
Human immunodeficiency virus (HIV) envelope binds to CXCR4 independently of CD4, and binding can be enhanced by interaction with soluble CD4 or by HIV envelope deglycosylation. J Virol (1998) 1.39
Delineation of human antibody responses to culture filtrate antigens of Mycobacterium tuberculosis. J Infect Dis (1998) 1.36
Complement activation by human monoclonal antibodies to human immunodeficiency virus. J Virol (1993) 1.36
Target cells for the activity of a synthetic adjuvant: muramyl dipeptide. Cell Immunol (1977) 1.36
Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6. J Virol (2001) 1.35
Surrogate marker of preclinical tuberculosis in human immunodeficiency virus infection: antibodies to an 88-kDa secreted antigen of Mycobacterium tuberculosis. J Infect Dis (1997) 1.35
Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J Immunol (1994) 1.35
Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes. J Virol (2000) 1.34
Immune response to levan. III. The capacity to produce anti-inulin antibodies and cross-reactive idiotypes appears late in ontogeny. J Immunol (1979) 1.34
A human T-independent B lymphocyte mitogen extracted from Nocardia opaca. J Immunol (1976) 1.33
Quantitation of beta 2-microglobulin and other immune characteristics in a prospective study of men at risk for acquired immune deficiency syndrome. JAMA (1984) 1.32
Characterization of structural and immunological properties of specific domains of Friend ecotropic and dual-tropic murine leukemia virus gp70s. J Virol (1984) 1.32